Novanta Inc. — FY2017 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2017; filed February 28, 2018. This is an annual report, not a standalone fourth-quarter filing. Dollar amounts are U.S. dollars.
Business context
Novanta supplies photonics, vision and precision-motion components and subsystems primarily to medical and advanced-industrial OEMs. Each end market represented approximately 50% of 2017 revenue. The company’s growth strategy emphasizes medical applications, product development, operational improvement and complementary acquisitions.
Financial results
| Metric | FY2017 | FY2016 |
|---|---|---|
| Revenue | $521.3 million | $384.8 million |
| Gross profit / margin | $220.5 million / 42.3% | $162.5 million / 42.2% |
| Operating income / margin | $57.2 million / 11.0% | $32.6 million / 8.5% |
| Net income attributable to Novanta | $60.1 million | $22.0 million |
| Diluted EPS | $1.13 | $0.63 |
| Cash from operating activities | $63.4 million | $47.8 million |
Revenue rose 35.5%; management attributed $105.8 million, or 27.5 percentage points, of the increase to the net effect of acquisitions and the prior discontinuation of radiology products. Foreign exchange reduced revenue by $1.9 million. The filing reports an unusual $26.4 million nontaxable gain when Novanta obtained control of Laser Quantum. A $20.2 million adjustment to the estimated redemption value of Laser Quantum’s redeemable noncontrolling interest reduced FY2017 EPS by $0.57; it was charged to retained earnings, not net income.
Segment revenue and operating income were: Photonics $232.4 million and $51.3 million; Vision $183.1 million and $7.9 million; Precision Motion $105.9 million and $27.1 million. Segment gross margins were 45.7%, 37.8% and 44.0%, respectively. Vision returned to operating profitability from a $1.3 million loss in 2016; Precision Motion’s margin was affected by supply-chain transition and production-quality issues.
Cash, debt and liquidity
Year-end cash was $100.1 million, versus $68.1 million in 2016. Operating cash flow was $63.4 million; investing cash outflow was $177.4 million, primarily reflecting acquisitions; financing cash inflow was $143.3 million. Capital expenditures were $9.1 million. Novanta forecast 2018 capital expenditures of approximately $12–15 million and stated operating cash flows should cover operating and capital needs for at least the next 12 months.
Year-end debt principal was approximately $237.8 million: $88.3 million of term loans and $149.5 million drawn on the revolving facility. The facility was expanded to $325 million; $175.5 million remained available. The company reported covenant compliance, with a 2.14 consolidated leverage ratio against a 4.00 limit and fixed-charge coverage of 5.63 against a 1.50 minimum. Debt matures in May 2021. A February 2018 amendment, after year-end, relaxed certain leverage limits.
Material changes, outlook and risks
- 2017 acquisitions: WOM for $134.9 million, an additional approximately 35% of Laser Quantum for $31.1 million (raising ownership to approximately 76%), and ThingMagic for $19.1 million. The acquired businesses contributed $102.7 million of reported 2017 revenue, according to selected financial data.
- Management did not provide specific revenue or earnings guidance. It cited growth opportunities in minimally invasive surgery, DNA sequencing, life sciences, laser materials processing, robotics, automation and metrology.
- The company adopted a growth-through-acquisition strategy while significantly increasing debt; execution and integration, including systems and internal controls at acquired businesses, are important considerations. WOM and Laser Quantum were excluded from management’s and the auditor’s year-end internal-control assessments; the auditor nevertheless gave an unqualified opinion on the financial statements and concluded controls were effective for the assessed scope.
- Key risks include cyclical OEM capital spending, customer order volatility and cancellable backlog, competition and technology change, single- or limited-source suppliers, foreign-exchange exposure, international trade and political uncertainty, medical-device regulation, cybersecurity and ERP implementation, and potential impairment of goodwill and acquired intangibles.
- The U.S. Tax Cuts and Jobs Act caused a $2.8 million deferred-tax revaluation provision in 2017; tax accounting remained provisional, with final adjustments expected by December 2018. No material adverse outcome was anticipated for ordinary-course legal proceedings, but the filing cautions that outcomes cannot be assured.
Investor verification priorities
- Separate organic growth from acquisition contributions and assess whether acquired revenue and margins are sustainable.
- Review the $26.4 million acquisition gain and $20.2 million redeemable-interest adjustment when evaluating earnings and EPS quality.
- Monitor debt, available revolver capacity, covenant headroom, 2021 maturity and the terms of the February 2018 amendment.
- Track Vision and Precision Motion margin recovery, Celera Motion supply-chain issues, and integration of WOM, Laser Quantum and ThingMagic.
- Confirm final Tax Reform Act accounting and the expected impact of adopting Topic 606 in 2018; management expected no material revenue-recognition impact.